Video

Dr. Pagel on Ongoing Research With BTK Inhibitors in CLL

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Zanubrutinib (Brukinsa), which received an accelerated approval in November 2019 in mantle cell lymphoma, is also under investigation in CLL. The agent appears to be well tolerated with low rates of atrial fibrillation, hypertension, and major bleeding, says Pagel.

Other BTK inhibitors, known as reversible BTK inhibitors, are also under evaluation. At the 2019 ASH Annual Meeting, data were presented with ARQ-531, LOXO-305, and vecabrutinib. ARQ-531 has shown high response rates in a small number of patients, particularly in those with Richter’s transformation, says Pagel. LOXO-305 has also shown activity in patients who are resistant to irreversible BTK inhibitors, such as ibrutinib (Imbruvica) and acalabrutinib (Calquence). The last drug, vecabrutinib, has also shown encouraging data. With more follow-up, the field will be able to determine the optimal role of these agents, concludes Pagel.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity